Kailera Therapeutics announced it will present new clinical and real-world research on its obesity drug ribupatide at ObesityWeek 2026, including Phase 3 trial designs and analyses of obesity treatment needs. Ribupatide, a GLP-1/GIP receptor dual agonist, is being developed as both a weekly injection and daily oral pill to address diverse patient needs. The presentations highlight Kailera's focus on advancing obesity care with innovative therapies and expanding its pipeline globally. The company plans to start global Phase 3 trials for the oral formulation in early 2027.
Kailera Therapeutics is presenting new obesity drug research at ObesityWeek 2026. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: out of 150 priced US health stocks, 76 rose and 58 fell. Notable movers include ABEO at USD 2.59 with a 1-day change of +1.97% and Pluang order activity showing 71% Buy, HIMS at USD 22.54 down 1.77% with 100% Buy activity, and BNGO at USD 1.18 up 1.72% but with 100% Sell activity.
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
